Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STE 
STERIS plc (STE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: STE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $272.38
1 Year Target Price $272.38
| 3 | Strong Buy |
| 2 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.2% | Avg. Invested days 48 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 24.19B USD | Price to earnings Ratio 37.49 | 1Y Target Price 272.38 |
Price to earnings Ratio 37.49 | 1Y Target Price 272.38 | ||
Volume (30-day avg) 10 | Beta 0.92 | 52 Weeks Range 199.99 - 252.20 | Updated Date 08/15/2025 |
52 Weeks Range 199.99 - 252.20 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 0.93% | Basic EPS (TTM) 6.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When After Market | Estimate 2.26 | Actual 2.34 |
Profitability
Profit Margin 11.61% | Operating Margin (TTM) 17.85% |
Management Effectiveness
Return on Assets (TTM) 6.22% | Return on Equity (TTM) 9.74% |
Valuation
Trailing PE 37.49 | Forward PE 24.27 | Enterprise Value 26031677760 | Price to Sales(TTM) 4.34 |
Enterprise Value 26031677760 | Price to Sales(TTM) 4.34 | ||
Enterprise Value to Revenue 4.67 | Enterprise Value to EBITDA 18.49 | Shares Outstanding 98490600 | Shares Floating 98108462 |
Shares Outstanding 98490600 | Shares Floating 98108462 | ||
Percent Insiders 0.3 | Percent Institutions 96.8 |
Upturn AI SWOT
STERIS plc
Company Overview
History and Background
STERIS plc was founded in 1985 as Innovative Medical Technologies, Inc. in Mentor, Ohio. The company evolved through acquisitions and organic growth, becoming a leading provider of infection prevention and surgical products and services. In 2015, STERIS completed a corporate inversion, re-domiciling to Ireland and becoming STERIS plc.
Core Business Areas
- Healthcare: Provides sterilization and infection prevention products and services to healthcare facilities.
- Applied Sterilization Technologies (AST): Offers contract sterilization and lab services to medical device, pharmaceutical, and commercial industries.
- Life Sciences: Provides sterilization, cleaning, and infection control products, and services for pharmaceutical, research, and biopharmaceutical facilities.
Leadership and Structure
The current CEO is Dan Carestio. STERIS plc operates with a global organizational structure, with key executives overseeing various business segments and functional areas.
Top Products and Market Share
Key Offerings
- Steam Sterilizers: STERIS is a leading manufacturer of steam sterilizers used in healthcare and laboratory settings. The market is competitive, with Getinge being a major competitor. STERIS is positioned as one of the market leaders but market share data varies. Some estimates put it around 20-25% in the healthcare market segment.
- VHP (Vaporized Hydrogen Peroxide) Sterilizers: These are used for low-temperature sterilization in healthcare and life sciences. STERIS is a key player in this space. Competitors include ASP (Advanced Sterilization Products) a division of Fortive. Market share varies by geography, but STERIS holds a significant portion.
- Cleaning Chemistries: STERIS provides detergents and disinfectants for instrument reprocessing and environmental cleaning. Competitors include Ecolab and Metrex Research. Exact market share is difficult to pinpoint due to the fragmented nature of the cleaning chemistries market, but this is a significant revenue driver for STERIS.
- Contract Sterilization Services (AST): STERIS offers contract sterilization services (using gamma, E-beam and EtO) to medical device and pharmaceutical manufacturers. Competitors include Sotera Health. While no official market share data, STERIS is one of the largest contract sterilization providers.
Market Dynamics
Industry Overview
The infection prevention and sterilization market is driven by factors such as increasing healthcare spending, rising prevalence of healthcare-associated infections (HAIs), and stringent regulatory requirements. The contract sterilization market is driven by outsourcing trends and the complexity of sterilization processes.
Positioning
STERIS plc is a well-established player with a strong brand reputation and a comprehensive portfolio of products and services. The company benefits from its global presence, diverse customer base, and expertise in sterilization technologies.
Total Addressable Market (TAM)
The global sterilization equipment and consumables market is estimated to be in the billions of USD. STERIS is positioned to capture a substantial share of this TAM through its diverse product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Comprehensive product and service portfolio
- Global presence
- Established customer relationships
- Recurring revenue streams (services)
- Robust M&A strategy
Weaknesses
- Exposure to regulatory changes
- Dependence on healthcare spending
- Potential for product liability claims
- Sensitivity to economic cycles
- Integration risks from acquisitions
Opportunities
- Expansion into emerging markets
- Development of new sterilization technologies
- Increasing outsourcing of sterilization services
- Growing demand for infection prevention solutions
- Acquisitions of complementary businesses
Threats
- Intense competition
- Pricing pressures
- Technological obsolescence
- Changes in regulatory standards
- Economic downturns
Competitors and Market Share
Key Competitors
- GEHC
- SOTERA HEALTH (SHC)
- ECL
Competitive Landscape
STERIS plc competes on product innovation, service quality, and pricing. Its competitive advantage lies in its comprehensive product portfolio and established customer relationships.
Major Acquisitions
Cantel Medical
- Year: 2021
- Acquisition Price (USD millions): 4600
- Strategic Rationale: Expanded STERIS's endoscopy and dental segments and provided access to new technologies and markets.
Growth Trajectory and Initiatives
Historical Growth: STERIS plc has demonstrated consistent growth through organic initiatives and strategic acquisitions.
Future Projections: Consult analyst reports and company presentations for future growth projections.
Recent Initiatives: Recent initiatives include acquisitions, product launches, and expansion into new markets.
Summary
STERIS plc is a strong player in the infection prevention and sterilization market, benefiting from its diverse product portfolio and global presence. The company's growth has been fueled by acquisitions and organic initiatives. Potential challenges include intense competition and regulatory changes. Investors should also note how macroeconomic events can impact STERIS such as interest rate changes and recession fears.
Peer Comparison
Sources and Disclaimers
Data Sources:
- STERIS plc SEC filings, Investor Relations, Market Research Reports, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STERIS plc
Exchange NYSE | Headquaters Mentor, OH, United States | ||
IPO Launch date 1992-06-01 | President, CEO & Director Mr. Daniel A. Carestio | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17787 | Website https://www.steris.com |
Full time employees 17787 | Website https://www.steris.com | ||
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.